SFX by Ex Libris Inc.

Title:	In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
Source:	Science [0036-8075] Vassilev, L T yr:2004

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Ding, Q. "Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development." Journal of medicinal chemistry 56.14 (2013): 5979-5983.
description	2.	Tovar, C. "Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy." Proceedings of the National Academy of Sciences of the United States of America 103.6 (2006): 1888-1893.
description	3.	HOON, S. "Yeast chemical genomics and drug discovery: an update." Trends in Pharmacological Sciences 29.10 (2008): 499-504.
description	4.	Wang, B. "53BP1, a mediator of the DNA damage checkpoint." Science 298.5597 (2002): 1435-1438.
description	5.	Murray, Stephen A A. "IGF-1 activates p21 to inhibit UV-induced cell death." Oncogene 22.11: 1703-1711.
description	6.	Zhang, B. "Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development." ACS medicinal chemistry letters 5.2 (2014): 124-127.
description	7.	Hu, C. "Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors." Bioorganic & medicinal chemistry 20.4 (2012): 1417-1424.
description	8.	Ding, K. "Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction." Journal of medicinal chemistry 49.12 (2006): 3432-5.
description	9.	Chène, P. "Inhibiting the p53–MDM2 interaction: an important target for cancer therapy." Nature reviews. Cancer 3.2 (2003): 102-109.
description	10.	Vu, B. "Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development." ACS medicinal chemistry letters 4.5 (2013): 466-469.
description	11.	Tovar, C. "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models." Cancer research 73.8 (2013): 8-5472.
description	12.	Kim, In l. "Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an Î±-helix." Organic letters 8.9 (2006): 1751-1754.
description	13.	Yoo, E. "53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage." Oncogene 24.35 (2005): 5423-30.
description	14.	Houston, Jessica P P. "Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe." Journal of biomedical optics 10.5: 54010-54010.
description	15.	Chou, T.C. C. "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors." Advances in enzyme regulation 22.C (1984): 27-55.
description	16.	Vousden, Karen H. "p53 and PUMA: A deadly duo." Science 309.5741 (2005): 1685-1686.
description	17.	Ong, S. "Identifying the proteins to which small-molecule probes and drugs bind in cells." Proceedings of the National Academy of Sciences of the United States of America 106.Mar. 2 2009 (2009): 1-4622.
description	18.	Care, R. "The MET3 promoter: a new tool for Candida albicans molecular genetics." Molecular microbiology 34.4 (1999): 792-798.
description	19.	Vrancic, M. "Mammalian genome recombineering: Yeast, still a helper microorganism of choice?" Food technology and biotechnology 46.3 (2008): 237-251.
description	20.	Fan, Q. "A Dual Phosphoinositide-3-Kinase Î±/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN-Mutant Glioma." Cancer research 67.17 (2007): 7960-7965.